Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH

•Despite no approved treatments for NASH, several drug candidates have shown promise in early clinical trials.•Therapies targeting metabolic pathologies of NASH have shown efficacy to reduce hepatic fat content and improve fibrosis.•Many of these therapies have been rationally designed to mimic nuclear hormone or peptide hormone action.•Despite provocative preclinical findings of nuclear and peptide hormone combination, clinical translation remains unproven.